LILLY & Co ELI
CIK 59478 · Director, Chairman and CEO · last filed 2023-08-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.91B
Companies
10
Total Filings
26
Lifetime Open-Market Net
$1.57B
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
Filer Profile
Reported Address
LILLY CORPORATE CTRDROP CODE 1094
INDIANAPOLIS, IN 46285
Phone
(317) 276-2000
State of Incorporation
IN
Formerly Known As
LILLY ELI & CO (1994–2019)
LILLY ELI & CO ET AL (1994–1994)
Related Filers
LILLY ENDOWMENT INC — 483 joint filings, latest 2026-07-23
Ralph Alvarez — 161 joint filings, latest 2026-08-18
J Erik Fyrwald — 99 joint filings, latest 2026-08-18
Juan R Luciano — 97 joint filings, latest 2026-08-18
Donald A Zakrowski — 64 joint filings, latest 2026-08-11
Jackson P Tai — 62 joint filings, latest 2023-04-19
Gabrielle Sulzberger — 59 joint filings, latest 2026-08-18
David A Ricks — 49 joint filings, latest 2026-02-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Sigilon Therapeutics, Inc. (SGTX) Delisted | 10%+ Owner | 100 | $22.47 | $2.2K | $56.68M | 2 | 2023-08-14 |
| RNA | 10%+ Owner | 2,169,396 | $7.84 | $17.01M | $0 | 1 | 2020-06-16 |
| DERM | 10%+ Owner | 100 | $6.61 | $661 | $1.53B | 1 | 2020-02-20 |
| ELAN | 10%+ Owner | 0 | $22.14 | $0 | $0 | 1 | 2019-03-11 |
| ZYME | 10%+ Owner | 1,827,101 | $25.15 | $45.95M | -$15.35M | 14 | 2019-02-06 |
| CYPHERPUNK TECHNOLOGIES INC. (LPTX) Delisted | 10%+ Owner | — | $1.56 | — | $0 | 1 | 2018-08-13 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 100 | — | — | $0 | 1 | 2017-03-01 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 102,742 | $12.01 | $1.23M | $5.00M | 1 | 2016-04-14 |
| Receptos, Inc. (RCPT) Delisted | 10%+ Owner | 2,081,210 | — | — | $6.00M | 1 | 2013-11-21 |
| UTHR | 10%+ Owner | 5,251,394 | $541.70 | $2.84B | -$12.96M | 3 | 2011-07-06 |
Recent Filings · Page 2 of 3
26 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-09-18 | ZYME | Sell (S) | −15,874 | -$231.4K | EDGAR |
| 2018-09-14 | ZYME | Sell (S) | −30,959 | -$448.5K | EDGAR |
| 2018-09-12 | ZYME | Sell (S) | −15,777 | -$232.7K | EDGAR |
| 2018-09-04 | ZYME | Sell (S) | −700 | -$10.0K | EDGAR |
| 2018-08-31 | ZYME | Sell (S) | −5,752 | -$82.3K | EDGAR |
| 2018-08-16 | ZYME | Sell (S) | −3,000 | -$42.8K | EDGAR |
| 2018-08-14 | ZYME | Sell (S) | −6,429 | -$92.0K | EDGAR |
| 2018-08-13 | CYPHERPUNK TECHNOLOGIES INC. (LPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-08-07 | ZYME | Sell (S) | −1,650 | -$22.4K | EDGAR |
| 2018-08-03 | ZYME | Sell (S) | −19,400 | -$258.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.